ArticleJournal of substance abuse treatment2015
Supply of buprenorphine waivered physicians: the influence of state policies.
Article in Journal of substance abuse treatment, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02926482 (Test of a Workforce Development Intervention to Expand Buprenorphine Prescribers), which is not on this map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Test of a Workforce Development Intervention to Expand Buprenorphine Prescribers
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of State Office-Based Buprenorphine Treatment Laws Effective During 2022: Counseling, Dosage, and Visit Frequency Requirements.Substance use & addiction journal · 2024Pooled it
- Prescribers' satisfaction with delivering medications for opioid use disorder.Substance abuse treatment, prevention, and policy · 2021Trial
- Physicians' satisfaction with providing buprenorphine treatment.Addiction science & clinical practice · 2019Trial
- The payer's role in addressing the opioid epidemic: It's more than money.Journal of substance abuse treatment · 2019Trial
- Cost of pharmacotherapy for opioid use disorders following inpatient detoxification.The American journal of managed care · 2018Trial
- Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.Implementation science : IS · 2017Trial
- Growing importance of high-volume buprenorphine prescribers in OUD treatment: 2009-2018.Drug and alcohol dependence · 2024Observational
- Navigating addiction treatment during COVID-19: policy insights from state health leaders.Health affairs scholar · 2024Article
- Medical and genetic correlates of long-term buprenorphine treatment in the electronic health records.Translational psychiatry · 2024Article
- Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009-2018.Drug and alcohol dependence reports · 2023Article
- State Policy and the Breadth of Buprenorphine-Prescriber Networks in Medicaid Managed Care.Medical care research and review : MCRR · 2023Article
- Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads.Substance abuse · 2023Article
- Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment.JAMA health forum · 2023Article
- Building medication for opioid use disorder prescriber capacity during the opioid epidemic: Prescriber recruitment trends and methods.Journal of substance use and addiction treatment · 2023Article
- To Prescribe or Not to Prescribe?: Barriers and Motivators for Progressing Along Each Stage of the Buprenorphine Training and Prescribing Path.The journal of behavioral health services & research · 2023Article
- Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine.Substance abuse · 2022Article
- Medicaid Managed Care: Access To Primary Care Providers Who Prescribe Buprenorphine.Health affairs (Project Hope) · 2022Article
- Therapeutic relationships between Veterans and buprenorphine providers and effects on treatment retention.Health services research · 2022Article
- The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.Drug and alcohol dependence · 2022Article
- The impact of access to addiction specialist on attitudes, beliefs and hospital-based opioid use disorder related care: A survey of hospitalist physicians.Substance abuse · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Buprenorphine, an effective opioid use disorder treatment, can be prescribed only by buprenorphine-waivered physicians. We calculated the number of buprenorphine-waivered physicians/100,000 county residents using 2008-11 Buprenorphine Waiver Notification System data, and used multivariate regression models to predict number of buprenorphine-waivered physicians/100,000 residents in a county as a function of county characteristics, state policies and efforts to promote buprenorphine use. In 2011, 43% of US counties had no buprenorphine-waivered physicians and 7% had 20 or more waivered physicians. Medicaid funding, opioid overdose deaths, and specific state guidance for office-based buprenorphine use were associated with more buprenorphine-waivered physicians, while encouraging methadone programs to promote buprenorphine use had no impact. Our findings provide important empirical information to individuals seeking to identify effective approaches to increase the number of physicians able to prescribe buprenorphine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.